Annual Shareholder Meeting. Joachim Kreuzburg Chairman of the Board and CEO 03. April 2018
|
|
- Lesley Manning
- 5 years ago
- Views:
Transcription
1 Annual Shareholder Meeting Joachim Kreuzburg Chairman of the Board and CEO 03. April 2018
2 Disclaimer This presentation contains statements concerning Sartorius Stedim Biotech Group s future performance. These statements are based on assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we cannot guarantee that they will actually materialize. This is because our assumptions harbor risks and uncertainties that could lead to actual results diverging substantially from the expected ones. It is not planned to update our forwardlooking statements. Throughout this presentation, differences may be apparent as a result of rounding during addition.
3 Agenda FY 2017 Results 2018 Guidance Dividend Proposal Strategy and mid-term targets
4 Another year of solid growth in revenue and profit Continued profitable growth in a challenging market and FX environment Dampening effects only of temporary nature; strong finish to the year with double-digit order growth Progress in our multi-year investment program; portfolio expanded through acquisition of Umetrics Positive outlook for 2018 and beyond 4
5 Strong order intake; earnings influenced by FX headwinds Order intake in millions Sales revenue in millions EBITDA & margin 2 in millions EPS 3 in 1, , , , % 27.3% % % % % 1 Constant currencies 2 Underlying = excluding extraordinary items 3 Underlying EPS = based on net profit after non-controlling interest, adjusted for extraordinary items, amortization and based on a normalized financial result and tax rate 5
6 Different development in the regions Americas in millions EMEA in millions Asia Pacific in millions Sales by Regions in % EMEA ~ 43% Americas ~ 34% 1.08bn FY16 FY17 FY 16 FY17 FY16 FY17-3.5% +2.2% +21.4% Acc. to customers location; growth in constant currencies Asia Pacific ~ 23% Particularly the Americas & EMEA compare with a very high prior-year base; softer demand in the Americas and parts of Europe, additionally destocking by a few customers especially in Q Moreover, the Americas also influenced by transient manufacturing (Puerto Rico) and supply bottlenecks (cell culture media) Dynamic growth in Asia Pacific supported by some large equipment projects 6
7 Financial position remains very strong Key financial indicators Net debt to underlying EBITDA Sartorius Stedim Biotech Dec Dec Equity ratio in % Net debt in millions Net cash flow from operating activities in millions ,0 7
8 Considerable number of new jobs created again Group France % % + 7.8% + 4.8% Nearly 5,100 people; 367 new employees, thereof 36 relating to the acquisition of Umetrics 8
9 Balance sheet of the parent company Balance sheet structure in millions and % as at December 31, 2017 Assets Equity and Liabilities 14.5% % % % Non-current assets Current assets Equity Total liabilities 9
10 Share price now fully recovered after Q3 guidance adjustment 130% Market Capitalization 6.6 bn as of March 28, 2018 SSB +0.5% NASDAQ Biotech +9.0% CAC Small +21.1% SBF % 115% 100% 85% 70% Jan 2017 Feb Mar Apr May Jun Jul Aug Sept Oct Nov Dec Jan 2018 Feb Mar After nearly quadrupling over the past five years, share price development was volatile in 2017 Strong start into 2018: Share price rose by about 15% since beginning of January 10
11 Outlook for 2018 Sartorius Stedim Biotech FY 2017 FY 2018 Guidance Sales revenue growth 1 4.1% ~ 7% - 10% Underlying EBITDA margin 27.3% ~ +0.5pp 1 Capex ratio 12.6% ~ 15% 1 In constant currencies Growth guidance includes non-organic contribution by recent acquisition of ~ 0.5pp As a result from the US tax reform, SSB s tax rate is expected to decrease from 2018 onwards by 2pp to around 26% 11
12 Agenda FY 2017 Results 2018 Guidance Dividend Proposal Strategy and mid-term targets
13 Strong dividend increase yet again Earnings per share in Dividend per share in th dividend increase in succession Total profit distributed would increase by 9.5% from 38.7mn to 42.4mn Payout ratio 2 of 23.5% (2016: 21.9%) in line with SSB s dividend policy Figures for adjusted for stock split; rounded values 1 Subject to approval by the AGM 2 Relative to underlying net profit 13
14 Agenda FY 2017 Results 2018 Guidance Dividend Proposal Strategy and mid-term targets
15 Sustainable profitable growth Sales CAGR ~+14% EBITDA 1 margin +6.4pp +10.3% 477m % +15.9% Sales revenue EBITDA 1 margin in % +19.4% % +4.1% ~+7-10% 1.08bn ~+0.5pp ~ 1.5bn ~ e e Sales growth and CAGR in constant currencies 1 Excluding extraordinary items 2 Based on guidance 15
16 On track to meet 2020 targets Strategic initiatives Regional Further increase of sales force effectiveness Gain share in North America Leverage market growth in Asia 2020 targets ~ bn 1 Sales revenue Portfolio Alliances and acquisitions Own product development ~ 4 5 Organic ~ 1 5 Acquisitions Infrastructure Continued capacity expansion Drive digitalization and roll-out of efficient IT systems ~29-30% 1 EBITDA 2 margin 1 Based on 2015 fx rates 2 Excluding extraordinary items 16
17 Regional balance better reflecting end-markets Sales by region 2011 Sales by region 2017 Global pharmaceutical market ~ 477m CAGR ~ 1.08bn ~ 1.1tn Asia Pacific ~ 20% +17% Asia Pacific ~ 23% Asia Pacific ~ 26% Americas ~ 27% +15% Americas ~ 34% Americas ~ 51% EMEA ~ 53% +11% EMEA ~ 43% EMEA ~ 23% CAGR in constant currencies 17
18 Offering the widest portfolio covering PD, up- and downstream Process development Production Small-scale single-use bioreactors Q Cell culture media Q Cell line development services Q Testing in biosafety and bioanalytics Q Single-use technology for sampling Q Software for bioprocess data analysis Q Single-use centrifuges Q
19 Strong competence in data analytics established Acquisition of Sweden-based software suite Umetrics Powerful solutions for modeling and optimizing development and manufacturing processes for biopharmaceuticals Digitalization of processes gain importance on customers` side Possible applications along the complete process chain 19
20 Infrastructure prepared for further organic growth Yauco, Puerto Rico Doubling of fluid management and filter capacities ~15% Capex ratio Capex ratio currently on an elevated level in % ~ e 1 1 Based on guidance Goettingen, Germany Extension of filter capacities New ERP and extension of global IT infrastructure 20
21 Market fundamentals remain very attractive Favorable demographics 9bn people by 2050 of which >2bn 60yrs or older Rise of biosimilars >50% CAGR of biosimilar sales ~8% CAGR of biopharma market until Increasing healthcare spending +6.5% CAGR of worldwide prescription drug sales Favorable R&D pipeline; strong advances in gene and cell therapy >50% Share of biologics in pharma R&D pipeline 21
22 The Chinese market will become increasingly imporant China biologics market size RMB in bn Global biologics market growth outlook by region in % CAGR China biologics market size 2016 (in- $bn, e to 2021e) CAGR ~25% ~16% 20% 16% 12% 8% ~16% CAGR e ~9% ~7% % e e 0% China U.S. Europe Based on data from Frost & Sullivan 22
23 Acquisitions remain part of our strategy Acquisition criteria Portfolio Complementary products or technologies Market position Either among the Top 3 or unique position Integration Management capacity; cultural fit Price Fair valuation; reach SSBs` profitability level in 2-3 years Market environment Increasingly consolidated But many start-ups with innovative technologies 23
24 Our Sartorius 2025 targets and initiatives Strategic initiatives Regional Participate in strong Chinese market growth Continue to outgrow the important U.S. market Portfolio Adding high-impact innovation, e.g. digital tools Enhance process development capabilities Expand into adjacent applications Operations Accelerate workflows across the organization through digitalization Extend manufacturing base in Asia 2025 targets ~ 2.8bn 1 Sales revenue ~30% EBITDA margin 2025 ambition is based on 2017 currency exchange rates; non-organic revenue growth is accounted for the consolidation of companies acquired from 2018 onwards; EBITDA excluding extraordinary items 24
25 Thank you for your attention
Conference Call Preliminary FY 2017 Results Joachim Kreuzburg, CEO Rainer Lehmann, CFO January 31, 2018
Conference Call Preliminary FY 2017 Results Joachim Kreuzburg, CEO Rainer Lehmann, CFO January 31, 2018 Disclaimer This presentation contains statements concerning the future performance of the Sartorius
More informationConference Call First-Half 2017 Results. Joachim Kreuzburg, CEO July 21, 2017
Conference Call First-Half 2017 Results Joachim Kreuzburg, CEO July 21, 2017 Disclaimer This presentation contains statements concerning the future performance of the Sartorius Group and the Sartorius
More informationConference Call First-Quarter 2017 Results. Joachim Kreuzburg, CEO April 24, 2017
Conference Call First-Quarter 2017 Results Joachim Kreuzburg, CEO April 24, 2017 Disclaimer This presentation contains statements concerning the future performance of the Sartorius Group and the Sartorius
More informationConference Call Preliminary Full-Year 2018 Results. Joachim Kreuzburg (CEO), Rainer Lehmann (CFO) January 29, 2019
Conference Call Preliminary Full-Year 2018 Results Joachim Kreuzburg (CEO), Rainer Lehmann (CFO) January 29, 2019 Disclaimer This presentation contains statements concerning the future performance of the
More informationConference Call Preliminary FY 2015 Results
Conference Call Preliminary FY 205 Results Joachim Kreuzburg, CEO February, 206 Disclaimer This presentation contains statements concerning the future performance of the Sartorius Group and the Sartorius
More informationNine-month figures for 2017: Sartorius continues to grow profitably in a challenging environment
Nine-month figures for : Sartorius continues to grow profitably in a challenging environment Group revenue up 8.6%; despite unfavorable currency effects, earnings 1 up 7.3% The Lab Products & Services
More informationInvestors Presentation. February 2018
Investors Presentation Februar 2018 Disclaimer This presentation contains statements concerning Sartorius Stedim Biotech Group s future performance. These statements are based on assumptions and estimates.
More informationInvestors Presentation. June 2018
Investors Presentation June 2018 Disclaimer This presentation contains statements concerning Sartorius Stedim Biotech Group s future performance. These statements are based on assumptions and estimates.
More informationInvestors Presentation. September 2018
Investors Presentation September 2018 Disclaimer This presentation contains statements concerning Sartorius Stedim Biotech Group s future performance. These statements are based on assumptions and estimates.
More informationInvestors Presentation October 2018
Investors Presentation October 2018 Disclaimer This presentation contains statements concerning the future performance of the Sartorius Group. These statements are based on assumptions and estimates. Although
More informationSartorius Stedim Biotech: Growth dynamics temporarily dampened; continued strong mid-term perspectives
Investor Press News 2017 Nine-Month Figures Sartorius Stedim Biotech: Growth dynamics temporarily dampened; continued strong mid-term perspectives in millions unless otherwise specified 9 months 2017 9
More informationNine-month figures for 2018: Sartorius Stedim Biotech continues to grow by double digits
Nine-month figures for : Sartorius Stedim Biotech continues to grow by double digits Group sales revenue up 13.8%; order intake up 14.5%; earnings margin 28.1% Dynamic development across all product categories
More informationH Sartorius Group Conference Call. Joachim Kreuzburg, CEO July 25, Page 1
H1 2012 Sartorius Group Conference Call Joachim Kreuzburg, CEO July 25, 2012 Page 1 Disclaimer This presentation contains statements concerning the Sartorius and Sartorius Stedim Biotech Group s future
More informationEarnings Release Q1 2017
First-quarter figures: Sartorius starts off with double-digit growth Group sales revenue up 12.2%; earnings 1 up 17.0% Lab Products & Services shows very dynamic performance driven by organic growth and
More informationInvestors Presentation. April 2017
Investors Presentation April 2017 Disclaimer This presentation contains statements concerning Sartorius Stedim Biotech Group s future performance. These statements are based on assumptions and estimates.
More informationFirst-quarter figures: Sartorius Stedim Biotech off to a dynamic start into 2018
First-quarter figures: Sartorius Stedim Biotech off to a dynamic start into Group revenue up 9.8%; driven by positive development in all regions Exchange rate effects dampen profit growth Guidance for
More information0 First-Half Financial Report Key Figures for the First Half and Second Quarter of First-Half Financial Report
0 First-Half Financial Report Key Figures for the First Half and Second Quarter of 2018 First-Half Financial Report First-Half Financial Report Key Figures for the First Half and Second Quarter of 2018
More informationInvestors Presentation. August 2018
Investors Presentation August 2018 Disclaimer This presentation contains statements concerning Sartorius Stedim Biotech Group s future performance. These statements are based on assumptions and estimates.
More informationCombined Group Management Report
Combined Group Management Report 22 Group Management Report Structure and Management of the Group Structure and Management of the Group Sartorius AG 100% ~ 74% 100% Service and infrastructure companies
More informationSartorius Group First-Half Financial Report from January to June 2017
Sartorius Group First-Half Financial Report from January to June Key Figures for the First Half of In millions of unless otherwise specified Group Bioprocess Solutions Lab Products & Services reported
More informationEarnings Release 9M 2016
Nine-month Figures for : Sartorius Continues to Grow by Strong Double Digits Dynamic growth for the Bioprocess Solutions Division; positive development of the Lab Products & Services Division Earnings
More informationInvestors Presentation. March 2017
Investors Presentation March 2017 Disclaimer This presentation contains statements concerning the future performance of the Sartorius Group. These statements are based on assumptions and estimates. Although
More informationSartorius Stedim Biotech Group First-Half Financial Report from January to June 2014
Sartorius Stedim Biotech Group First-Half Financial Report from January to June Key Figures for the First Half of in millions of unless otherwise specified 2013 Growth in % Growth in % (in const. currencies)
More informationtwo industry leaders, one solution provider
two industry leaders, one solution provider Sartorius Stedim Biotech Group Six-Month Report January to June 2007 Material Events The Sartorius Stedim Biotech Group (SSB) resulted from the combination of
More informationSartorius Stedim Biotech Group Nine-Month Report from January to September 2011
Sartorius Stedim Biotech Group Nine-Month Report from January to September 2011 Business Development and Outlook Double-digit increase in sales revenue Underlying EBITA soared 22.0% Guidance for fiscal
More information0 First-Half Financial Report Key Figures for the First Half and Second Quarter of First-Half Financial Report
0 First-Half Financial Report Key Figures for the First Half and Second Quarter of First-Half Financial Report First-Half Financial Report Key Figures for the First Half and Second Quarter of 1 Key Figures
More informationSartorius Stedim Biotech Group First-Half Financial Report from January to June 2016
Sartorius Stedim Biotech Group First-Half Financial Report from January to June Key Figures for the First Half of in millions of unless otherwise specified 2015 Change in % Change in % cc 1 Sales Revenue
More informationInvestors Presentation. May 2017
Investors Presentation Ma 2017 Disclaimer This presentation contains statements concerning the future performance of the Sartorius Group. These statements are based on assumptions and estimates. Although
More informationSartorius Group 2018 Annual Report
Sartorius Group 2018 Annual Report Order Intake and Sales Revenue in millions 1,800 929.2 1,172.7 1,334.7 1,501.4 1,662.5 891.2 1,114.8 1,300.3 1,404.6 1,566.0 Underlying EBITDA and Margin 1) 186.8 263.2
More information37 th Annual JP Morgan Healthcare Conference. January 8, 2019
37 th Annual JP Morgan Healthcare Conference January 8, 2019 Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions.
More informationSartorius Stedim Biotech Group First-Half Financial Report January to June 2012
Sartorius Stedim Biotech Group First-Half Financial Report January to June 2012 Macroeconomic Environment and Sector Conditions Macroeconomic Environment The global economy continued to grow in the first
More informationFY 2017 Presentation
FY 2017 Presentation 1 2 At a glance Overview FY 2017 YoY revenue growth of 2.2% to EUR 82.5 mn (FY 2016: EUR 80.7 mn) in a challenging year after 13.5% decline at the end of H1/17 (compared YoY) New order
More informationFull year Press Conference February 27, Rice Powell - CEO
Full year 2017 Press Conference February 27, 2018 Rice Powell - CEO Press Conference FY 2017 1 Safe harbor statement: This presentation includes certain forward-looking statements within the meaning of
More informationFinancial & Business Highlights For the Year Ended June 30, 2017
Financial & Business Highlights For the Year Ended June, 17 17 16 15 14 13 12 Profit and Loss Account Operating Revenue 858 590 648 415 172 174 Investment gains net 5 162 909 825 322 516 Other 262 146
More informationSartorius Group 2015 Annual Report
Sartorius Group 2015 Annual Report Order Intake and Sales Revenue in millions 1,200 749.5 866.8 912.3 819.6 929.2 1,172.7 733.1 845.7 887.3 791.6 891.2 1,114.8 Underlying EBITDA and Margin 1) 136.6 161.1
More informationDANAHER TO ACQUIRE GE LIFE SCIENCES BIOPHARMA BUSINESS ( GE Biopharma ) February 25, 2019
DANAHER TO ACQUIRE GE LIFE SCIENCES BIOPHARMA BUSINESS ( GE Biopharma ) February 25, 2019 Forward Looking Statements Statements in this presentation and the accompanying call that are not strictly historical,
More informationDean Foods. Earnings Report. February 11, 2009
Dean Foods Fourth Quarter and Year End 2008 Earnings Report February 11, 2009 Forward Looking Statements The following statements made in this presentation are forward looking and are made pursuant to
More informationCommon stock prices 1. New York Stock Exchange indexes (Dec. 31,1965=50)2. Transportation. Utility 3. Finance
Digitized for FRASER http://fraser.stlouisfed.org/ Federal Reserve Bank of St. Louis 000 97 98 99 I90 9 9 9 9 9 9 97 98 99 970 97 97 ""..".'..'.."... 97 97 97 97 977 978 979 980 98 98 98 98 98 98 987 988
More informationInvestor Presentation February 2019
Investor Presentation February 2019 Dr. Reddy s Laboratories Limited Hyderabad, India BSE: 500124 NSE: DRREDDY NYSE: RDY Safe Harbor Statement This presentation contains forward-looking statements and
More informationANNOUNCEMENT OF PRELIMINARY RESULTS
The leading high service distributor to engineers worldwide ANNOUNCEMENT OF PRELIMINARY RESULTS YEAR ENDED 31 MARCH 2009 29 May 2009 Agenda Overview and current trading Ian Mason Financial performance
More informationAnnual General Meeting Fiscal Year 2016
Annual General Meeting Fiscal Year 2016 Oberhausen, Germany, JÜRG OLEAS, CEO CHECK AGAINST DELIVERY. Agenda 1 Fiscal Year 2016 2 Focus on the Future 3 Outlook for Fiscal Year 2017 2 Order intake* (EUR
More informationMedia and Financial Analysts Meeting 2017 Carlo Gavazzi Holding AG
Media and Financial Analysts Meeting 2017 Carlo Gavazzi Holding AG Media and Financial Analysts Meeting 2017 June 22, 2017 Media and Financial Analysts Meeting 2017 AGENDA FOR TODAY WELCOME & OVERVIEW
More informationAgenda. 1. Highlights FY 2012 Results. 2. Operational Performance Priorities for Financials. 5. Conclusion
1MARCH 2013 Legal Disclaimer Information in this presentation may involve guidance, expectations, beliefs, plans, intentions or strategies regarding the future. These forward-looking statements involve
More informationFULL YEAR 2018 PRESS CONFERENCE FEBRUARY 20, Rice Powell CEO. Copyright
FULL YEAR 2018 PRESS CONFERENCE FEBRUARY 20, 2019 Rice Powell CEO Copyright Safe harbor statement: This presentation includes certain forward-looking statements within the meaning of Section 27A of the
More informationKONE Result presentation 2018 JANUARY 24, 2019 HENRIK EHRNROOTH, PRESIDENT & CEO ILKKA HARA, CFO
KONE Result presentation 2018 JANUARY 24, 2019 HENRIK EHRNROOTH, PRESIDENT & CEO ILKKA HARA, CFO Q4 2018 Highlights Orders received and sales grew in all regions and all businesses Adjusted EBIT returned
More informationMerck FY/Q Financial Summary for Investors and Analysts
Merck FY/Q4 2017 Financial Summary for Investors and Analysts Performance amid headwinds: Healthcare sound core business; successful launches of Mavenclad & Bavencio Life Science strong performance above
More informationSeptember Colliers International Group Inc. Investor Presentation
September 2018 Colliers International Group Inc. Investor Presentation Basis Of Presentation All amounts in millions of US Dollars unless otherwise noted. Adjusted EBITDA ( AEBITDA ) and Adjusted EPS (
More informationMedia and Financial Analysts Meeting 2018 Carlo Gavazzi Holding AG
Media and Financial Analysts Meeting 2018 Carlo Gavazzi Holding AG Media and Financial Analysts Meeting 2018 June 28, 2018 Media and Financial Analysts Meeting 2018 AGENDA FOR TODAY WELCOME & OVERVIEW
More informationKONE Q APRIL 25, 2018 HENRIK EHRNROOTH, PRESIDENT & CEO ILKKA HARA, CFO
KONE 2018 APRIL 25, 2018 HENRIK EHRNROOTH, PRESIDENT & CEO ILKKA HARA, CFO 2018 Highlights Solid growth in orders received with stabilizing margins Profitability continued to be burdened Good progress
More informationDecember Colliers International Group Inc. Investor Presentation
December 2018 Colliers International Group Inc. Investor Presentation Basis Of Presentation All amounts in millions of US Dollars unless otherwise noted. Adjusted EBITDA ( AEBITDA ) and Adjusted EPS (
More informationFULL YEAR REPORT, 2017 TELEPHONE/AUDIO CONFERENCE 8 FEBRUARY 2018, AT CET TOMMY ANDERSSON, PRESIDENT AND CEO HELENA WENNERSTRÖM, EVP AND CFO
TELEPHONE/AUDIO CONFERENCE 8 FEBRUARY 2018, AT 15.30 CET TOMMY ANDERSSON, PRESIDENT AND CEO HELENA WENNERSTRÖM, EVP AND CFO DIRECT LINK AUDIOCAST: HTTPS://TV.STREAMFABRIKEN.COM/BULTEN Q4 2017 TELECONFERENCE:
More informationInvestor Conference Call Q Results
Science For A Better Life Investor Conference Call Q1 2009 Results Werner Wenning, CEO April 29 2009 Q1 2009 Investor Conference Call Werner Wenning Disclaimer This presentation may contain forward-looking
More informationCheuvreux 11th German Corporate Conference 2012 Frankfurt Main; January 17, Page 1
Cheuvreux 11th German Corporate Conference 2012 Frankfurt Main; January 17, 2012 Page 1 Disclaimer This presentation contains statements concerning the Sartorius Groups future performance. These statements
More informationLonza Reports Best First Half in History with Continued Strong Momentum
Pharma&Biotech Lonza Reports Best First Half in History with Continued Strong Momentum Richard Ridinger CEO Lonza Additional Information and Disclaimer Lonza Group Ltd has its headquarters in Basel, Switzerland,
More informationKONE Q JULY 19, 2017 HENRIK EHRNROOTH, PRESIDENT & CEO ILKKA HARA, CFO
KONE Q2 2017 JULY 19, 2017 HENRIK EHRNROOTH, PRESIDENT & CEO ILKKA HARA, CFO Q2 2017 highlights Good overall execution Profitability burdened by several headwinds Stabilization in China Good improvement
More informationKONE Result presentation 2017 JANUARY 25, 2018 HENRIK EHRNROOTH, PRESIDENT & CEO ILKKA HARA, CFO
KONE Result presentation 2017 JANUARY 25, 2018 HENRIK EHRNROOTH, PRESIDENT & CEO ILKKA HARA, CFO Q4 2017 Highlights Orders received grew in all regions and their margin stabilized in the fourth quarter
More informationZEBRA TECHNOLOGIES. William Blair Growth Stock Conference June 16, 2016
ZEBRA TECHNOLOGIES William Blair Growth Stock Conference June 16, 2016 Safe Harbor Statement Statements made in this presentation which are not statements of historical fact are forward-looking statements
More informationKION UPDATE CALL Q Gordon Riske, CEO Thomas Toepfer, CFO Wiesbaden, 7 May 2015
KION UPDATE CALL 2015 Gordon Riske, CEO Thomas Toepfer, CFO Wiesbaden, 7 May 2015 AGENDA 1 Highlights Gordon Riske 2 Market update Gordon Riske 3 Financial update Thomas Toepfer 4 Outlook Gordon Riske
More informationQ Results. Lars Brorsen (CEO) Christoph Hobo (CFO) November 22, 2018
Q3 2018 Results Lars Brorsen (CEO) Christoph Hobo (CFO) November 22, 2018 Agenda 1. Highlights Q3 2018 2. Market outlook 3. Detailed results review 4. Company outlook 5. Q&A Appendix 1 Business summary
More informationSartorius Stedim Biotech Group Reference Document 2013
Sartorius Stedim Biotech Group Reference Document 2013 Order Intake and Sales Revenue in millions Underlying EBITDA and EBITA in millions 700 409.9 442.6 500.2 553.9 614.9 401.2 432.9 477.3 544.0 588.4
More information2017 Full Year Results
A GLOBAL LEADER IN METAL FLOW ENGINEERING 2017 Full Year Results 1 March 2018 Patrick André Chief Executive 1 Disclaimer This presentation, which has been prepared by Vesuvius plc (the Company ), includes
More informationJacky Lo Chief Finance Officer, Yum China
Jacky Lo Chief Finance Officer, Yum China Cautionary Language Regarding Forward-Looking Statements Forward-Looking Statements. Our presentation may contain forward-looking statements within the meaning
More informationResults FY 2017 Schaeffler AG. Conference Call March 7, 2018 Munich
Results FY 2017 Schaeffler AG Conference Call Munich Disclaimer This presentation contains forward-looking statements. The words "anticipate", "assume", "believe", "estimate", "expect", "intend", "may",
More informationSolid performance in a mixed environment
2014 Full Year Solid performance in a mixed environment Paris, 2014 Full Year Paris, Solid performance and sustained shareholder return in a mixed environment Sales growth, enhanced competitiveness Strong
More informationQ Earnings Presentation. Rainer Beaujean, Speaker of the Management Board and CFO April 12, 2018
Q1 2018 Earnings Presentation Rainer Beaujean, Speaker of the Management Board and CFO April 12, 2018 Disclaimer This presentation may contain certain forward-looking statements, including assumptions,
More informationQ Sales January 22 nd 2019
Q4 20 Sales January 22 nd 2019 Highlights Solid sales growth in Q4 and FY 20: +1.9% LFL in Q4 and +1.4% in FY Group sales up +1.9% LFL vs +1.1% over first 9 months Food e-commerce sales up by more than
More informationAnalyst Presentation Q May 8, 2014 Dr Matthias Zieschang, CFO
Analyst Presentation Q1 2014 May 8, 2014 Dr Matthias Zieschang, CFO Slide 2 Disclaimer This document has been prepared by Fraport solely for use in this presentation. The information contained in this
More informationANNUAL GENERAL MEETING METRO AG. 15 February 2019
ANNUAL GENERAL MEETING METRO AG 15 February 2019 DISCLAIMER AND NOTES To the extent that statements in this presentation do not relate to historical or current facts, they constitute forward-looking statements.
More informationINTERIM PRESENTATION Q October 2018
INTERIM PRESENTATION 25 October JUAN VARGUES, PRESIDENT & CEO HIGHLIGTHS Organic growth Good organic growth in EMEA Flat organic growth in Americas despite -7% RV OEM APAC down due to softer market in
More informationINEOS STYROLUTION. Q1/ 2018 Investor Earnings Call
INEOS STYROLUTION Q1/ 2018 Investor Earnings Call Disclaimer The following presentation includes forward-looking statements, within the meaning of the US securities laws, based on our current expectations
More informationUK retail sales 137, ,967 26% International retail sales 214, ,954 39%
2 3 000s Six months to 28 February 2013 Six months to 29 February 2012 Change Group revenues 1 359,731 269,926 33% Retail sales 352,263 262,921 34% UK retail sales 137,579 108,967 26% International retail
More informationAnnual Accounts Annika Falkengren President & CEO
Annual Accounts 2014 Annika Falkengren President & CEO Unique economic environment Key Interest rates % 2.00 1.80 1.60 1.40 1.20 1.00 0.80 0.60 0.40 0.20 0.00 Jan-14 Sweden Norway Eurozone Feb-14 Mar-14
More informationYear-end Report January-December, 2012
Year-end Report January-December, 20 Lars Nyberg President and CEO Record-high Free cash flow during 20 Net sales SEK 4,898 million (4,804) Increased 1.2% in local currencies EBITDA* SEK 36,059 million
More informationData. Insights. Results.
Image Area Data. Insights. Results. Raymond James 26 th Annual Institutional Investors Conference March 2005 Safe Harbor Certain statements we make today are forward-looking within the meaning of US federal
More information2007 Revenue and Results. 2007: strong increase in results Strengthened growth momentum. February 15 th, 2008
2007 Revenue and Results 2007: strong increase in results Strengthened growth momentum February 15 th, 2008 2007 revenue and results Agenda A successful 2007 Be the recognized industry leader John Glen
More informationJefferies Global Healthcare Conference
Jefferies Global Healthcare Conference June 7, 2012 2012 PAREXEL International Safe Harbor This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act
More informationBANK OF AMERICA MERRILL LYNCH GLOBAL INDUSTRIALS & EU AUTOS CONFERENCE
BANK OF AMERICA MERRILL LYNCH GLOBAL INDUSTRIALS & EU AUTOS CONFERENCE London Mar 18, 2015 Emmanuel Babeau, Deputy CEO and CFO 1 Disclaimer All forward-looking statements are Schneider Electric management
More informationSMART STEEL. Q Results. Detlef Borghardt, CEO Dr. Matthias Heiden, CFO. August 14, 2018
SMART STEEL Q2 218 Results Detlef Borghardt, CEO Dr. Matthias Heiden, CFO August 14, 218 Agenda Business Summary Guidance adjustment FY 218 Market update Regional trends: Status and profitability trend
More informationBusiness Update. USPP Conference Miami. Luis Damasceno Group CFO Michael Williams Group Finance Director & Treasurer January 2019
Business Update USPP Conference Miami Luis Damasceno Group CFO Michael Williams Group Finance Director & Treasurer 23-25 January 2019 www.alsglobal.com IMPORTANT NOTICE AND DISCLAIMER This presentation
More informationAgenda. Consolidated Financial Results for the Fiscal Year 2013 and Guidance for Sustainable Growth
Consolidated Financial Results for the Fiscal Year 2013 and Guidance for Sustainable Growth François-Xavier Roger Chief Financial Officer May 8, 2014 Agenda Key highlights Revenue Income statement Balance
More informationSIX MONTHS REPORT, JAN JUN 2018
SIX MONTHS REPORT, JAN JUN 2018 TELEPHONE/AUDIO CONFERENCE 11 JULY 2018, AT 11.00 CET TOMMY ANDERSSON, PRESIDENT AND CEO HELENA WENNERSTRÖM, EVP AND CFO DIRECT LINK AUDIOCAST: HTTPS://TV.STREAMFABRIKEN.COM/BULTEN
More informationInvestor Presentation
14 MAR 2016 Investor Presentation 4Q and FY 2015 Results Hussein Hachem, CEO Bashar Obeid, CFO Management Update 4Q 2015 Results FY 2015 Results Long-term Performance Outlook & Guidance Page 1 Disclaimer
More informationAnnouncement of Q Results
Announcement of Q3 2008 Results Conference Call October 15, 2008 2:00 p.m. CEST Dr. Axel Herberg, CEO Hans-Jürgen Wiecha, CFO 0 Disclaimer This presentation may contain certain forward-looking statements,
More informationInterim Report January September 2014
Interim Report January September 2014 Johan Dennelind President & CEO Capital Markets Day summary 2018 2013 2014 2015 2016 2017 The New TeliaSonera Big changes Stabilize & shape Transform & perform Transform
More informationFY2017 Earnings presentation. Landis+Gyr June 5, 2018
FY2017 Earnings presentation Important notices This presentation includes forward-looking information and statements including statements concerning the outlook for our businesses. These statements are
More informationKONE Q OCTOBER 26, 2017 HENRIK EHRNROOTH, PRESIDENT & CEO ILKKA HARA, CFO
KONE Q3 2017 OCTOBER 26, 2017 HENRIK EHRNROOTH, PRESIDENT & CEO ILKKA HARA, CFO Q3 2017 highlights Orders received returned to growth in China with positive contribution from focused pricing actions Roll-out
More informationPerformance Report October 2018
Structured Investments Indicative Report October 2018 This report illustrates the indicative performance of all Structured Investment Strategies from inception to 31 October 2018 Matured Investment Strategies
More informationFor personal use only
2016 Annual General Meeting 18 NOVEMBER 2016 YOUR BOARD Greg Ridder Ruslan Kogan David Shafer Harry Debney Independent, Non-Executive Chairman Founder & CEO CFO & COO Independent, Non-Executive Director
More informationBoard of Directors Zurich, 24 March, 2009 Dufry Presentation - Full Year 2009 Results
Dufry Presentation - Full Year 2009 Results March 2010 1 Legal Disclaimer Information in this presentation may involve guidance, expectations, beliefs, plans, intentions or strategies regarding the future.
More informationInterim Report January-June, 2014
Interim Report January-June, 2014 Johan Dennelind President and CEO All regions contribute to stable margin Group service revenues flat - net sales negatively impacted by Spain Underlying EBITDA maintained
More informationElectrocomponents 2017 half-year financial results. 18 November 2016
Electrocomponents 2017 half-year financial results 18 November 2016 Agenda Overview of results Lindsley Ruth Financial results and performance update David Egan Performance Improvement Plan Lindsley Ruth
More informationPERFORMANCE AND TRAJECTORY
PERFORMANCE AND TRAJECTORY José (Joe) E. Almeida Chairman, President and CEO May 21, 2018 Safe Harbor Statement This presentation includes forward-looking statements concerning Baxter s financial results,
More informationCORESTATE Capital. Preliminary Results FY Management Presentation. 20 February 2018
CORESTATE Capital Management Presentation Preliminary Results FY 2017 20 February 2018 Disclaimer This presentation contains forward-looking statements that involve a number of risks and uncertainties.
More information2018 Half Year Results
A GLOBAL LEADER IN METAL FLOW ENGINEERING 2018 Half Year Results 26 July 2018 Patrick André Chief Executive 1 Disclaimer This presentation, which has been prepared by Vesuvius plc (the Company ), includes
More informationKION GROUP AG Q Update Call. Gordon Riske (CEO), Anke Groth (CFO) Frankfurt, 26 July 2018
KION GROUP AG Q2 Update Call Gordon Riske (CEO), Anke Groth (CFO) Frankfurt, 26 July Agenda 1. Highlights 2. Market Update 3. Financial Update 4. Outlook 2 KION GROUP AG Q2 Update Call 26 July Q2 Strategic
More informationSTRATEC H Financial Results. Conference Call - August 15, 2018
STRATEC H1 2018 Financial Results Conference Call - August 15, 2018 SAFE HARBOR STATEMENT Forward-looking statements involve risks. This company presentation contains various statements concerning the
More informationDSM Capital Markets Day 2018
DSM Capital Markets Day 2018 Targets 2021 focused on growth, cash and value Geraldine Matchett CFO ROYAL DSM CAPITAL MARKETS DAY LONDON (UK) - 20 JUNE 2018 Safe harbor statement This presentation may contain
More information2010 First half performance
2010 First half performance Solid progression in sales and profits Recovery in growth projects August 2, 2010 Benoît Potier, Chairman and CEO Pierre Dufour, Senior Executive Vice-President Jean-Pierre
More informationValmet focus on profitability improvement
Valmet focus on profitability improvement SEB Nordic Seminar 2015, Copenhagen Pasi Laine, President and CEO Agenda Valmet Roadshow 1 2 3 4 Valmet overview Financial targets Q3/2014 in brief Conclusions
More informationSMART STEEL. Q Results. Detlef Borghardt, CEO Dr. Matthias Heiden, CFO. November 8, 2018
SMART STEEL Q3 218 Results Detlef Borghardt, CEO Dr. Matthias Heiden, CFO November 8, 218 Agenda Business Summary Preliminaries confirmed Market update Segments: Status and profitability trend in the regions
More information